欢迎访一网宝!您身边的知识小帮手,专注做最新的学习参考资料!
首页 > 其他 >

国际英语新闻:Over 8.3 million people a

一网宝 分享 时间: 加入收藏 我要投稿 点赞

BEIJING, Aug. 22 (Xinhua) -- An inactivated COVID-19 vaccine developed by China has started phase-3 clinical trials in Argentina, according to its developer China National Biotec Group (CNBG), which is affiliated to Sinopharm.

The launch ceremony of the phase-3 clinical trials was held in Beijing Friday after the CNBG obtained the certificate of approval for the process.

This is an achievement brought about by CNBG's international cooperation in a bid to develop a COVID-19 vaccine. The inactivated vaccine received approval for phase-3 clinical trials in the United Arab Emirates on June 23, and in Peru and Morocco on Thursday.

The CNBG will work together with a company in Argentina to promote research and development related to the inactivated vaccine.

Liu Jingzhen, chairman of Sinopharm, said the phase-3 clinical trials will help fight the epidemic and contribute to the building of a community of health for all.

精选图文

221381
领取福利

微信扫码领取福利

微信扫码分享